摘要: The current year has been mainly characterized by the publication in Europe of guidelines on diagnosis and treatment heart failure (HF) USA an update pharmacological HF with praiseworthy effort to provide consistent recommendations drug therapy.1–3 Therefore, large majority new evidences published at end 2015 first quarter 2016 are included these publications. However, as always happens, scientific community provided, more recently, additional relevant information from studies very for management patients HF. The most important novel ESC can be summarized following points.
oup.com
uzh.ch
core.ac.uk 
sci-hub.se 参考文章(27)
Pardeep S Jhund, Michael Fu, Edmundo Bayram, Chen-Huan Chen, Marta Negrusz-Kawecka, Arvo Rosenthal, Akshay S Desai, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg, Michael R Zile, John JV McMurray, Milton Packer, None, Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal. ,vol. 36, pp. 2576- 2584 ,(2015) , 10.1093/EURHEARTJ/EHV330
David K. Packham, Henrik S. Rasmussen, Philip T. Lavin, Mohamed A. El-Shahawy, Simon D. Roger, Geoffrey Block, Wajeh Qunibi, Pablo Pergola, Bhupinder Singh, Sodium Zirconium Cyclosilicate in Hyperkalemia The New England Journal of Medicine. ,vol. 372, pp. 222- 231 ,(2015) , 10.1056/NEJMOA1411487
Akshay S. Desai, John J.V. McMurray, Milton Packer, Karl Swedberg, Jean L. Rouleau, Fabian Chen, Jianjian Gong, Adel R. Rizkala, Abdel Brahimi, Brian Claggett, Peter V. Finn, Loren Howard Hartley, Jiankang Liu, Martin Lefkowitz, Victor Shi, Michael R. Zile, Scott D. Solomon, Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients European Heart Journal. ,vol. 36, pp. 1990- 1997 ,(2015) , 10.1093/EURHEARTJ/EHV186
John JV McMurray, Milton Packer, Akshay S Desai, Jianjian Gong, Martin P Lefkowitz, Adel R Rizkala, Jean L Rouleau, Victor C Shi, Scott D Solomon, Karl Swedberg, Michael R Zile, None, Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine. ,vol. 371, pp. 993- 1004 ,(2014) , 10.1056/NEJMOA1409077
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi, None, Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine. ,vol. 373, pp. 2117- 2128 ,(2015) , 10.1056/NEJMOA1504720
, J. J. V. McMurray, S. Adamopoulos, S. D. Anker, A. Auricchio, M. Bohm, K. Dickstein, V. Falk, G. Filippatos, C. Fonseca, M. A. Gomez-Sanchez, T. Jaarsma, L. Kober, G. Y. H. Lip, A. P. Maggioni, A. Parkhomenko, B. M. Pieske, B. A. Popescu, P. K. Ronnevik, F. H. Rutten, J. Schwitter, P. Seferovic, J. Stepinska, P. T. Trindade, A. A. Voors, F. Zannad, A. Zeiher, J. J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, T. McDonagh, U. Sechtem, L. A. Bonet, P. Avraamides, H. A. Ben Lamin, M. Brignole, A. Coca, P. Cowburn, H. Dargie, P. Elliott, F. A. Flachskampf, G. F. Guida, S. Hardman, B. Iung, B. Merkely, C. Mueller, J. N. Nanas, O. W. Nielsen, S. Orn, J. T. Parissis, P. Ponikowski, , , ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. ,vol. 33, pp. 1787- 1847 ,(2012) , 10.1093/EURHEARTJ/EHS104
Joanne Simpson, Pardeep S Jhund, Jose Silva Cardoso, Felipe Martinez, Arend Mosterd, Felix Ramires, Adel R Rizkala, Michele Senni, Iain Squire, Jianjian Gong, Martin P Lefkowitz, Victor C Shi, Akshay S Desai, Jean L Rouleau, Karl Swedberg, Michael R Zile, John JV McMurray, Milton Packer, Scott D Solomon, PARADIGM-HF Investigators and Committees, Comparing LCZ696 with Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores An Analysis of Mortality and Morbidity in PARADIGM-HF Journal of the American College of Cardiology. ,vol. 66, pp. 2059- 2071 ,(2015) , 10.1016/J.JACC.2015.08.878
Bertram Pitt, George L. Bakris, David A. Bushinsky, Dahlia Garza, Martha R. Mayo, Yuri Stasiv, Heidi Christ‐Schmidt, Lance Berman, Matthew R. Weir, Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on
RAAS
inhibitors European Journal of Heart Failure. ,vol. 17, pp. 1057- 1065 ,(2015) , 10.1002/EJHF.402
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi, Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial European Heart Journal. ,vol. 37, pp. 1526- 1534 ,(2016) , 10.1093/EURHEARTJ/EHV728
Scott D. Solomon, Brian Claggett, Akshay S. Desai, Milton Packer, Michael Zile, Karl Swedberg, Jean L. Rouleau, Victor C. Shi, Randall C. Starling, Ömer Kozan, Andrej Dukat, Martin P. Lefkowitz, John J.V. McMurray, Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial Circulation-heart Failure. ,vol. 9, pp. 1- ,(2016) , 10.1161/CIRCHEARTFAILURE.115.002744